Cellares announced a $257 million Series D financing co‑led by investment funds managed by BlackRock and Eclipse, bringing the company’s total capital raised to $612 million.
The Series D adds a new group of global investors, including accounts advised by T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, and Gates Frontier, alongside continued participation from existing backers DC Global Ventures, DFJ Growth, and Willett Advisors.
The round will fund the global buildout of automated integrated development and manufacturing organization (IDMO) smart factories across South San Francisco, CA; Bridgewater, NJ; Leiden, the Netherlands; and Kashiwa City, Japan, to enable commercial launch and unconstrained manufacturing of cell therapies for hundreds of thousands of patients annually.
Cellares expects to support clinical manufacturing in the first half of 2026, with commercial-scale manufacturing beginning in 2027.
Last March, Cellares and Cabaletta Bio concluded their Technology Adoption Program (TAP) utilizing Cellares’ automated cell therapy manufacturing platform for Cabaletta’s lead clinical candidate, a CD19-targeting CAR-T cell therapy for patients with autoimmune diseases. According to Cellares, the Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene editing, activation, and expansion. Each unit operation met predefined in-process requirements. The automated process delivered drug products that met pre-defined quality ranges.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!